Likelihood of Approval and Phase Transition Success Rate Model – Opaganib in Coronavirus Disease 2019 (COVID-19) Pneumonia
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Opaganib in Coronavirus Disease 2019 (COVID-19) Pneumonia report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Opaganib in Coronavirus Disease 2019 (COVID-19) Pneumonia Drug Details:
Opaganib (ABC-294640) is under development for the treatment of neuroblastoma, renal interstitial fibrosis, advanced, unresectable intra-hepatic, gastrointestinal acute radiation syndrome (GI-ARS), mustard gas (sulfur mustard) poisoning, perihilar and extra-hepatic cholangiocarcinoma, non-small cell lung cancer, advanced solid tumors, bile duct cancer (cholangiocarcinoma), metastatic castration resistant prostate cancer, Pseudomonas aeruginosa-induced lung injury, radiation-induced lung inflammation and fibrosis, acute kidney injury, pneumonia, coronavirus disease (COVID-19) and Ebola virus infection, chikungunya virus, respiratory syncytial virus (RSV) infection, type 2 diabetes and obesity, inflammatory bowel disease (IBD) including ulcerative colitis and Crohn’s disease. It is administered orally as a capsule. It is an aryladamantane derivative. The drug candidate acts by targeting sphingosine kinase-2 (SK2), dihydroceramide desaturase and glucosylceramide synthase. The drug candidate is a new chemical entity. The drug candidate was also under development for multiple myeloma, hepatocellular carcinoma, colorectal cancer, pancreatic cancer, diffuse large B-cell lymphoma, Kaposi sarcoma and retinopathy, primary effusion lymphoma, liver transplantation, ulcerative colitis and rheumatoid arthritis. It was also under development as a radioprotectant for the prevention of mucositis and head and neck cancer.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Opaganib LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports